WILMINGTON, Del. — AstaZeneca and Merck’s Lynzparza (olaparib) tablets were approved by the Food and Drug Administration, as well as given an expanded indication by the regulatory agency.
Specialty Pharmacy News
The Centers for Disease Control and Prevention estimate that more than 1,000 Americans are treated in emergency departments for misusing prescription opioids daily.
StopDIRfees.com includes information and testimonials about how DIR fees are imposed, as well as an online petition and contact information for elected officials.
Mylan has invested $250 million in expanding its antiretroviral production capabilities, enabling it to produce 4 billion antiretroviral tablets and capsules each year, the company said.
In clinical trials, 33% of patients treated with Radicava showed a lower rate of decline in the loss of physical function, compared with those on a placebo.
As it named a new president, Diplomat reported Q2 results that showed increased revenue, but highlighted the margin pressure it’s seeing as the result of DIR fees.
Vyxeos combines two commonly used chemotherapies into a single formulation to treat patients with certain types of high-risk acute myeloid leukemia.
The single-tablet hepatitis C regimen is now approved for use in patients with hepatitis C that are co-infected with HIV.
The company’s pharmaceutical distribution services segment saw revenue of $37 billion, a 4.7% increase over the same quarter last year, with the AmerisourceBergen Drug Corp. seeing a revenue increase of 4.5% due largely to organic sales growth.